Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • MSA
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Corporate Presentations
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jun 24, 2020 6:30am EDT

ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders

Jun 17, 2020 6:30am EDT

ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19

May 28, 2020 6:30am EDT

ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus

May 20, 2020 6:30am EDT

ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform

May 19, 2020 6:30am EDT

ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays

May 13, 2020 6:30am EDT

ProMIS Neurosciences Announces First Quarter 2020 Results

May 12, 2020 6:30am EDT

ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test

May 06, 2020 6:30am EDT

ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS

Apr 30, 2020 6:30am EDT

ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases

Apr 22, 2020 2:43pm EDT

ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing

  • arrow_back
  • 1…
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …19
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2023 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy